TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of preventable unnecessary laparoscopies and explorative laparotomies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of Cholesteryl Ester Storage Disease
Endpoint domain: Mortality/survival
Primary endpoint: postoperative course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Therapeutic Failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of clinical or laboratory toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Five Times Sit-to-Stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Final Angiographic Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Epigenetic modifications in cytokines genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: American Spinal Injury Association (ASIA) Impairment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Left ventricular compliance and distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: upper respiratory tract infection incidence
Endpoint domain: Adverse events/effects
Primary endpoint: lower respiratory tract infection incidence
Endpoint domain: Adverse events/effects
Primary endpoint: 2-Hour Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serum 25-hydroxyvitamin D >=50 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients who achieve the early response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-time lumbar puncture success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative changes in activated CD4+/CD8+ T-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitative changes in pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitative changes in the central memory cell pool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC and Css,max of EE and LNG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in OACIS-I Average Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transit time of the released granules after capsule disintegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience of chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Development of Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-intervention Aerobic Bacterial Colony Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-intervention Anaerobic Bacterial Colony Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sustained Virological Response 12 weeks post-treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Unintended medication discrepancy
Endpoint domain: Adverse events/effects
Primary endpoint: QoR40 on the Day After Surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Degree of urinary continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk of Experiencing a Primary Outcome Event (POE)
Endpoint domain: Mortality/survival
Primary endpoint: Plasma anti-FXa concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited or Unsolicited Symptoms Reporting During the Post-vaccination Period
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects Reporting the Occurrence of Unsolicited Adverse Events Related to Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Procedure or device related complications
Endpoint domain: Adverse events/effects
Primary endpoint: All Death
Endpoint domain: Mortality/survival
Primary endpoint: Ischemic stroke, systemic embolism
Endpoint domain: Adverse events/effects
Primary endpoint: early and sustained viral responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cup Stacking Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrete Sequence Production Task Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of oxygen desaturation SpO2<95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in total scores of Spleen Qi Deficiency Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Levocetirizine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Levocetirizine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life of stroke survivors
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Systemic inflammatory markers (C-Reactive Protein, Erythrocyte Sedimentation Ratio, neutrophil to lymphocyte ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Achieving SLE Responder Index Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patient Reported Pain-free Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in meibomian gland function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in insulin resistance (Matsuda Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma drug concentration versus time curve from hour 0 to the time with a last quantifiable level (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma drug concentration versus time curve extrapolated to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy intake ad libitum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: appetite feelings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: surviving transplants
Endpoint domain: Mortality/survival
Primary endpoint: Death, all-cause
Endpoint domain: Mortality/survival
Primary endpoint: Change in Mean Central Subfield Thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration of TNB-383B (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of waist circumference at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of waist circumference at 5 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in range of cervical flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in range of right and left lateral rotations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scar Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of EER
Endpoint domain: Adverse events/effects
Primary endpoint: clinical sensitivity and specificity of GeneSearch™ BLN Test Kit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Death or Reinfarction or Disabling Stroke
Endpoint domain: Mortality/survival
Primary endpoint: DNA damage detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Disruption Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total T Cavg in the Eugonadal Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric Mean Anti-PRP Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of carotid plaque stability assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Level of forward flexion of the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obtention of induced pluripotent stem cell line (iPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Efficacy Endpoint
Endpoint domain: Physiological/clinical
Primary endpoint: Incidence of early graft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Depression performance measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life-patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Outcome Prediction Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Zinc status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute Procedural Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of patients without Atrial Fibrillation recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High sensitive TroponinT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global Rank Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of Treatment Related Serious Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Incisional Surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Craving for Cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured diffusing capacity for carbon monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nodal yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Loss of Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Global Impressions-Severity (CGI-S) scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Brief Psychiatric Rating Scale derived (BPRSd) total scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of facet joints showing pain and effusion/edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serologic inflammatory responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Predictive value of PET/CT for detecting immune-related adverse events (irAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax under fasting condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast under fasting condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax under fed condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast under fed condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Percent Change in the Number of Non-inflamed Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Oswestry Disability Index Score Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean number of XRNTX doses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: systolic blood pressure amplification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: F3-F2 Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timely and appropriate outpatient medical follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects with viral load below the limit of quantitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-thioguanine (6TG) levels in erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) of tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) of dutasteride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of dutasteride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate/Pyruvate Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of device-related failure injections
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of stool sample collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the mesiodistal inclination of the canine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Incidence of Early Onset Pulmonary Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Impact of Events Scale-Revised (IES-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of patients with abnormalities of the immune system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Identification of genetic variants associated with PID
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Implants That Survived
Endpoint domain: Mortality/survival
Primary endpoint: Number of genomic contributors to inherited cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of identified novel mechanisms of tumorigenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of NIF-guidance in robotic pulmonary segmentectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of high-output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need for intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response rate at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHAT-P Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory cytokine expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Body composition assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glutamate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Types, frequency, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: progression-free survival rate of six month
Endpoint domain: Mortality/survival
Primary endpoint: Triclosan Concentration in Dental Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Month Progression-free Survival Rate (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Oro-cecal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average whole-gut transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: renal clearances (CLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: bacterial richness (observed species)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Hepatocellular carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Retention in Treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Relative variation of molar ratio [oxaluria / creatinuria]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of stage 3 AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inappropriate Shock Free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in scores on Western Aphasia Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HCV antibody prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of HCV-MOSAIC risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in HIV RNA in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rise in CD4 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expressions of activating FcγRs and inhibiting receptor (FcγRIIb) on monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physical and Functional Well-being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Severity of Treatment-related Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Neurotoxicity Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of GI Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RAPID3 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appetite sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time needed to fall asleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Levels of proteins and cytokines in ostomy effluent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Infective bowel dysfunction (PI-BD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rates of Abstinence From Cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful engraftment of deceased or living donor uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live-born child per embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: Survival post-donation
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetics of rilpivirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients using the intervention for at least four weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Days and extent of bleeding and spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sustained Viral Response (SVR) 12 Weeks After Completing All Study Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing at Least 1 Adverse Event (AE)
Endpoint domain: Adverse events/effects